Streetbeat News

Stock Prices

IPAR

Inter Parfums reported Q1 sales of $324.00M, missing the analyst consensus estimate of $335.05M by 3.30%, but marking a 3.94% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:56 pm

LSTR

Landstar System reported Q1 2024 earnings of $1.32 per share, surpassing the $1.31 estimate, with sales of $1.171B exceeding the $1.122B forecast. This represents an 18.45% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:55 pm

ORLY

O'Reilly Automotive's stock is trading lower following the announcement of their Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:54 pm

ORN

Orion Group Holdings (ORN) reported Q1 2024 adjusted EPS of $(0.12), surpassing the $(0.18) estimate, indicating a 33.33% beat and a 62.5% improvement from last year's $(0.32) per share loss. However, their Q1 sales of $160.672M fell short of the $174.751M estimate by 8.06%, though it's a slight increase of 0.94% from the previous year's $159.174M.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:53 pm

SNSE

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) announced it will present topline clinical data from its Phase 1/2 trial of SNS-101 at the 2024 ASCO Annual Meeting. SNS-101 is a conditionally active, human monoclonal antibody targeting VISTA, aimed at treating cancer. The data includes results from a study of SNS-101 alone or in combination with cemiplimab in patients with advanced solid tumors.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:52 pm

OCEA

Ocean Biomedical, Inc. has received a notice from Nasdaq due to the late filing of its annual report on Form 10-K. This notice is a standard procedure for companies that fail to meet Nasdaq's filing deadlines. Ocean Biomedical is expected to address this issue promptly to remain in compliance with Nasdaq's listing requirements.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:52 pm

ME

23andMe Holding Co. (NASDAQ:ME) announced its plans to present preliminary efficacy and biomarker data for its anti-CD200R1 antibody, 23ME-00610, at the 2024 ASCO Annual Meeting. The data comes from the Phase 2a portion of an ongoing Phase 1/2a clinical trial targeting neuroendocrine and ovarian cancer. The company highlighted the discovery of 23ME-00610 through its proprietary database, leveraging genetic variants associated with immune diseases and cancer risks. Preliminary results show favorable pharmacokinetics and a promising safety profile for 23ME-00610.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:51 pm

PLAY

Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) announced the appointment of Darin Harper as the new Chief Financial Officer, effective June 17, 2024. Harper, previously CFO of Main Event Entertainment and with extensive experience in the entertainment and finance sectors, will succeed Michael Quartieri, who will retire but ensure a smooth transition until June 16, 2024. The company highlights Harper's strategic insights and track record as key to driving future growth.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:50 pm

CMG

During a conference call, an executive from Chipotle Mexican Grill indicated that the company expects its second quarter comparable sales (comps) to be the highest of the year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:49 pm

ATEK

Athena Technology Acquisition Corp. II has received a notice from the NYSE American indicating that it is not in compliance with the exchange's continued listing requirements. This development could impact the company's stock listing status if corrective measures are not taken promptly.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:49 pm